Announced details
Pharmaceutical and biotechnology sectors, biotechnology venture industry, capital markets and management strategy
The Company's outside director position will change from vacant to Tsuzuki Shinya (都築伸弥). Tsuzuki Shinya (都築伸弥) serves as Head of Investor Relations at Nxera Pharma Co.,Ltd. The capital, personnel and business relationships between the two companies are Not disclosed.
A biotechnology venture listed on the TSE Prime Market. Tsuzuki Shinya (都築伸弥) serves as Head of Investor Relations. Other information on its location, representative, capital, year of establishment and business activities is Not disclosed.
The disclosure states that the Company aims to apply Tsuzuki Shinya (都築伸弥)'s knowledge and network to management and grow into a leading biotechnology venture in Japan. The impact on specific financial performance figures is Not disclosed.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Counterparty | Nxera Pharma Co.,Ltd. (Securities code: 4565) |
| Counterparty overview | A biotechnology venture listed on the TSE Prime Market. Tsuzuki Shinya (都築伸弥) serves as Head of Investor Relations. Other information on its location, representative, capital, year of establishment and business activities is Not disclosed. |
| Relationship with the Company | The Company's outside director position will change from vacant to Tsuzuki Shinya (都築伸弥). Tsuzuki Shinya (都築伸弥) serves as Head of Investor Relations at Nxera Pharma Co.,Ltd. The capital, personnel and business relationships between the two companies are Not disclosed. |
| Launch date | 26 March 2026 (date of appointment decision; actual) |
| Applicable area | Pharmaceutical and biotechnology sectors, biotechnology venture industry, capital markets and management strategy |
| Impact on Business Performance | The disclosure states that the Company aims to apply Tsuzuki Shinya (都築伸弥)'s knowledge and network to management and grow into a leading biotechnology venture in Japan. The impact on specific financial performance figures is Not disclosed. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To apply Tsuzuki Shinya (都築伸弥)'s experience as an analyst covering the pharmaceutical and biotechnology sectors, his knowledge of the industry and capital markets, and his extensive network to management, with the aim of growing into a leading biotechnology venture in Japan.